Want to see SPRO full AI Analyst Report?
Top Page
Spero Therapeutics
(NASDAQ:SPRO)
Select Model
Select Model
Rating:59Neutral
Price Target:
$1.00
▼(-15.97% Downside)
Action:Reiterated
Date:07/24/26
The score is driven primarily by mixed financial quality—strong recent profitability and a low-debt balance sheet, but unstable revenue and historically inconsistent cash generation. Technically, the stock is in a pronounced downtrend despite oversold indicators. Valuation looks attractive on a low P/E, and recent corporate events (FDA approval plus licensing/financing that extends runway) provide a notable fundamental tailwind, partially tempered by dilution risk from increased share authorization.
Positive Factors
Regulatory Milestone
U.S. FDA approval for Utebzi is a durable structural achievement: it converts a clinical asset into an approved product under the GSK license, creating potential ongoing royalty and milestone cash flows, validating Spero’s infectious-disease R&D and strengthening long-term partner economics.
Negative Factors
Partnership-Driven Revenue
Reliance on collaboration payments and milestone-triggered cash creates structurally lumpy, unpredictable revenue. Without a diversified product portfolio or recurring sales, funding and growth hinge on achieving trial and regulatory milestones or securing external capital, raising durability risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Milestone
U.S. FDA approval for Utebzi is a durable structural achievement: it converts a clinical asset into an approved product under the GSK license, creating potential ongoing royalty and milestone cash flows, validating Spero’s infectious-disease R&D and strengthening long-term partner economics.
Read all positive factors
Spero Therapeutics (SPRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$69.48M
Dividend YieldN/A
Average Volume (3M)2.39M
Price to Earnings (P/E)4.3
Beta (1Y)1.65
Revenue Growth93.50%
EPS GrowthN/A
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.27
Shares Outstanding57,901,493
10 Day Avg. Volume3,870,189
30 Day Avg. Volume2,385,343
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.21
Price to Sales (P/S)2.19
P/FCF Ratio-10.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.67
Revenue Forecast (FY)$800.00K
Spero Therapeutics Business Overview & Revenue Model
Company Description
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases wi...
How the Company Makes Money
Spero Therapeutics’ revenue model has primarily been partnership- and financing-driven rather than product-sales-driven. As a clinical-stage company, it has generally not depended on recurring revenue from marketed drugs; instead, when revenue has...
Spero Therapeutics Earnings Call Summary
Earnings Call Date:Aug 12, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The earnings call reflected a positive outlook with significant achievements, particularly the successful Phase III trial for Tebipenem HBr and the improved financial metrics. However, challenges remain in the SPR720 program. Overall, the positive developments notably outweigh the negative aspects.Positive Updates
Successful Phase III PIVOT-PO Trial for Tebipenem HBr
The Phase III PIVOT-PO trial evaluating Tebipenem HBr for complicated urinary tract infections met its primary endpoint and was stopped early for efficacy, demonstrating non-inferiority to intravenous imipenem-cilastatin.
Negative Updates
SPR720 Trial Challenges
The Phase IIa proof-of-concept study for SPR720 did not meet its primary endpoint, and there were potential dose-limiting safety signals, including reversible grade 3 hepatotoxicity in the high-dose cohort.
Read all updates
Q2-2025 Updates
Positive
Negative
Successful Phase III PIVOT-PO Trial for Tebipenem HBr
The Phase III PIVOT-PO trial evaluating Tebipenem HBr for complicated urinary tract infections met its primary endpoint and was stopped early for efficacy, demonstrating non-inferiority to intravenous imipenem-cilastatin.
Read all positive updates
Company Guidance
During Spero Therapeutics' second quarter 2025 earnings call, significant progress was highlighted, particularly in their lead clinical program for Tebipenem HBr targeting complicated urinary tract infections (cUTIs). The Phase III PIVOT-PO trial was stopped early for efficacy, demonstrating Tebipenem HBr's non-inferiority to intravenous imipenem-cilastatin, with primary endpoint achievement noted in a test of cure visit. The trial's early conclusion resulted in cost savings, extending the company's cash runway into 2028. Financially, Spero reported a second-quarter revenue of $14.2 million, up from $10.2 million in the prior year, mainly due to collaboration revenue from GSK. R&D expenses decreased from $23.7 million to $10.7 million year-over-year, while G&A expenses slightly increased to $5.9 million. The net loss narrowed significantly to $1.7 million from $17.9 million in the previous year, with a diluted net loss per share of $0.03 compared to $0.33. Looking ahead, Spero focuses on regulatory approval of Tebipenem HBr, with FDA action anticipated in the second half of 2026, supported by contingent milestone opportunities with GSK, potentially totaling $351 million.Spero Therapeutics Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
72
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 54.77M | 59.62M | 47.98M | 103.78M | 48.58M | 3.07M |
| Gross Profit | 54.77M | 59.62M | -48.78M | 52.34M | 48.58M | 3.07M |
| EBITDA | 14.89M | 8.83M | -72.48M | 27.15M | -42.94M | -87.17M |
| Net Income | 15.23M | 8.57M | -68.57M | 22.81M | -46.41M | -89.76M |
Balance Sheet | ||||||
| Total Assets | 59.02M | 68.92M | 110.54M | 182.39M | 124.80M | 171.07M |
| Cash, Cash Equivalents and Short-Term Investments | 56.13M | 40.27M | 52.89M | 76.33M | 109.11M | 146.40M |
| Total Debt | 2.47M | 2.90M | 4.30M | 5.54M | 6.65M | 7.33M |
| Total Liabilities | 6.09M | 9.90M | 64.42M | 75.50M | 48.87M | 82.78M |
| Stockholders Equity | 52.93M | 59.02M | 46.12M | 106.89M | 75.93M | 88.29M |
Cash Flow | ||||||
| Free Cash Flow | 7.24M | -12.62M | -23.44M | -32.99M | -7.73M | -64.35M |
| Operating Cash Flow | 7.24M | -12.62M | -23.44M | -32.99M | -7.73M | -64.35M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 33.81M | 7.67M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 221.00K | -29.55M | 84.05M |
Spero Therapeutics Technical Analysis
Negative
1.19
Price Trends
2.18
Negative
2.38
Negative
2.36
Negative
Market Momentum
-0.32
Positive
20.90
Positive
5.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRO, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 2.18, and below the 200-day MA of 2.36, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 20.90 is Positive, neither overbought nor oversold. The STOCH value of 5.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SPRO.
Spero Therapeutics Risk Analysis
Spero Therapeutics disclosed 66 risk factors in its most recent earnings report. Spero Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Spero Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $69.48M | 4.34 | 35.58% | ― | 93.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $39.37M | -3.52 | -92.69% | ― | ― | 37.68% | |
47 Neutral | $39.09M | -1.02 | -346.03% | ― | ― | 28.53% | |
44 Neutral | $11.96M | -1.11 | -150.61% | ― | ― | 53.06% | |
42 Neutral | $53.97M | -0.40 | -666.47% | ― | -100.00% | 46.40% | |
42 Neutral | $46.29M | -0.93 | -127.30% | ― | ― | 49.74% |
* Healthcare Sector Average
SPRO
Spero Therapeutics
1.17
-1.09
-48.23%
INO
Inovio Pharmaceuticals
0.68
-0.79
-53.95%
NNVC
NanoViricides
1.52
-0.07
-4.40%
MCRB
Seres Therapeutics
4.83
-9.95
-67.32%
PDSB
PDS Biotechnology
0.69
-0.43
-38.75%
COCP
Cocrystal Pharma
0.82
-1.12
-57.73%
Spero Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Spero Therapeutics inks major CD40L and royalty deals
Positive
Jul 15, 2026
On July 8, 2026, Spero Therapeutics signed a global license and cross-license deal with Innovent Biologics for SP001, granting Spero exclusive rights to develop and commercialize the third-generation anti-CD40L antibody outside Greater China while...
Business Operations and StrategyShareholder Meetings
Spero Therapeutics Expands Stock Incentive Plan and Authorization
Positive
Jun 25, 2026
At its June 23, 2026 annual meeting, Spero Therapeutics stockholders approved a 2026 Stock Incentive Plan authorizing the issuance of up to 12,895,866 shares of common stock for equity-based compensation. At the same meeting, shareholders also app...
Business Operations and StrategyProduct-Related Announcements
Spero Therapeutics secures FDA approval for Utebzi
Positive
Jun 22, 2026
On June 17, 2026, Spero Therapeutics and GSK announced that the U.S. Food and Drug Administration approved Utebzi (tebipenem pivoxil), an oral antibiotic for adults with complicated urinary tract infections, including pyelonephritis, who have limi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.